132 related articles for article (PubMed ID: 27276518)
1. Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine.
Akazawa T; Uchida Y; Tachikawa M; Ohtsuki S; Terasaki T
Mol Pharm; 2016 Jul; 13(7):2443-56. PubMed ID: 27276518
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
3. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine.
Stephens RH; Tanianis-Hughes J; Higgs NB; Humphrey M; Warhurst G
J Pharmacol Exp Ther; 2002 Dec; 303(3):1095-101. PubMed ID: 12438532
[TBL] [Abstract][Full Text] [Related]
4. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
[TBL] [Abstract][Full Text] [Related]
5. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.
Jin M; Shimada T; Yokogawa K; Nomura M; Ishizaki J; Piao Y; Kato Y; Tsuji A; Miyamoto K
Biochem Pharmacol; 2006 Oct; 72(8):1042-50. PubMed ID: 16939683
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models.
Uchida Y; Ohtsuki S; Terasaki T
Drug Metab Dispos; 2014 Oct; 42(10):1719-26. PubMed ID: 25061162
[TBL] [Abstract][Full Text] [Related]
7. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.
Jin M; Shimada T; Yokogawa K; Nomura M; Kato Y; Tsuji A; Miyamoto K
Int J Pharm; 2006 Feb; 309(1-2):81-6. PubMed ID: 16384676
[TBL] [Abstract][Full Text] [Related]
8. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Atlas of Cytochrome P450, UDP-Glucuronosyltransferase, and Transporter Proteins in Jejunum of Morbidly Obese Subjects.
Miyauchi E; Tachikawa M; Declèves X; Uchida Y; Bouillot JL; Poitou C; Oppert JM; Mouly S; Bergmann JF; Terasaki T; Scherrmann JM; Lloret-Linares C
Mol Pharm; 2016 Aug; 13(8):2631-40. PubMed ID: 27347605
[TBL] [Abstract][Full Text] [Related]
10. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
[TBL] [Abstract][Full Text] [Related]
11. Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport.
Sadiq MW; Uchida Y; Hoshi Y; Tachikawa M; Terasaki T; Hammarlund-Udenaes M
PLoS One; 2015; 10(5):e0118638. PubMed ID: 25932627
[TBL] [Abstract][Full Text] [Related]
12. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
[TBL] [Abstract][Full Text] [Related]
13. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
Nakanishi H; Yonezawa A; Matsubara K; Yano I
Eur J Pharmacol; 2013 Jun; 710(1-3):20-8. PubMed ID: 23588114
[TBL] [Abstract][Full Text] [Related]
14. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G; Rostami-Hodjegan A
Drug Metab Dispos; 2016 Mar; 44(3):476-80. PubMed ID: 26842595
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
16. Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics.
Zamek-Gliszczynski MJ; Goldstein KM; Paulman A; Baker TK; Ryan TP
Drug Metab Dispos; 2013 Jun; 41(6):1174-8. PubMed ID: 23569176
[TBL] [Abstract][Full Text] [Related]
17. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Dec; 94(12):2632-43. PubMed ID: 16258992
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.
Makhey VD; Guo A; Norris DA; Hu P; Yan J; Sinko PJ
Pharm Res; 1998 Aug; 15(8):1160-7. PubMed ID: 9706044
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
20. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells.
Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G;
Drug Metab Dispos; 2016 Mar; 44(3):297-307. PubMed ID: 26631742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
